The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials DOI Creative Commons
Rebekah M. Ahmed, Olivier Piguet, Catherine J. Mummery

и другие.

The Lancet Regional Health - Western Pacific, Год журнала: 2025, Номер 55, С. 101492 - 101492

Опубликована: Фев. 1, 2025

SummaryIn the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with burdens on healthcare system that may limit access to treatment and care for patients. Often patients remote rural regions those low income are disadvantaged. Many clinical trials biased recruiting a homogenous group does not represent cultural linguistic diversity, meaning generalisability is limited. This viewpoint discusses barriers early offers framework address including provision infrastructure, regulatory change patient education.

Язык: Английский

The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials DOI Creative Commons
Rebekah M. Ahmed, Olivier Piguet, Catherine J. Mummery

и другие.

The Lancet Regional Health - Western Pacific, Год журнала: 2025, Номер 55, С. 101492 - 101492

Опубликована: Фев. 1, 2025

SummaryIn the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with burdens on healthcare system that may limit access to treatment and care for patients. Often patients remote rural regions those low income are disadvantaged. Many clinical trials biased recruiting a homogenous group does not represent cultural linguistic diversity, meaning generalisability is limited. This viewpoint discusses barriers early offers framework address including provision infrastructure, regulatory change patient education.

Язык: Английский

Процитировано

0